Epigenetic regulation of Wnt signaling pathway in urological cancer

Epigenetics

Volumn 5, Issue 4, 2010, Pages 343-351

  Costa, Vera L ^a   Henrique, Rui ^a,c   Ribeiro, Franclim R ^b,c   Carvalho, João R ^a,c   Oliveira, Jorge ^b   Lobo, Francisco ^b   Teixeira, Manuel R ^b,c   Jerónimo, Carmen ^a,c  

^a Cancer Epigenetics Group   (Portugal)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; GENOMIC DNA; GROWTH FACTOR; MESSENGER RNA; PROTEIN CTNNB1; PROTEIN WIF1; SECRETED FRIZZLED RELATED PROTEIN 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; WNT PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER MUCOSA; CANCER CELL CULTURE; CANCER LOCALIZATION; CONTROLLED STUDY; DNA EXTRACTION; DNA FLANKING REGION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROSTATE; PROSTATE CARCINOMA; PROTEIN METHYLATION; SIGNAL TRANSDUCTION; TUMOR GENE; URINARY TRACT CANCER;

EID: 77954662435     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.5.4.11749     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
2. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 2003; 129:199-221.
3. Gavert N, Ben-Ze'ev A. β-catenin signaling in biological control and cancer. J Cell Biochem 2007; 102:820-8.
4. Aguilera O, Muñoz A, Esteller M, Fraga MF. Epigenetic alterations of the Wnt/β-catenin pathway in human disease. Endocr Metab Immune Disord Drug Targets 2007; 7:13-21.
5. Roth W, Wild-Bode C, Platten M, Grimmel C, Melkonyan HS, Dichgans J, et al. Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene 2000; 19:4210-20.
6. Takada T, Yagi Y, Maekita T, Imura M, Nakagawa S, Tsao S-W, et al. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci 2004; 95:741-4.
7. Suzuki H, Watkins DN, Jair K-W, Schuebel KE, Markowitz SD, Chen WD, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36:417-22.
8. Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, et al. Wnt inhibitory factor-1 is silenced by promoter methylation in human lung cancer. Cancer Res 2004; 64:4717-20.
9. Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, et al. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005; 116:584-91.
10. Ai L, Tao Q, Zhong S, Fields CR, Kim W-J, Lee MW, et al. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 2006; 27:1341-8.
11. Takagi H, Sasaki S, Suzuki H, Toyota M, Maruyama R, Nojima M, et al. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol 2008; 43:378-89.
12. Hoque MO, Prencipe M, Poeta ML, Barbano R, Valori VM, Copetti M, et al. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev 2009; 18:2694-700.
13. Verras M, Sun Z. Roles and regulation of Wnt signaling and β-catenin in prostate cancer. Cancer Lett 2006; 237:22-32.
14. Bilim V, Kawasaki T, Katagiri A, Wakatsuki S, Takahashi K, Tomita Y. Altered expression of β-catenin in renal cell cancer and transitional cell cancer with the absence of β-catenin gene mutations. Clin Cancer Res 2000; 6:460-6.
15. Henrique RM, Costa VL, Jeronimo C. Methylation-based biomarkers for early detection of urological cancer. Crit Rev Oncog 2007; 13:265-82.
16. Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, et al. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res 2005; 65:10423-30.
17. Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H, et al. Combination analysis of methylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 2006; 12:2109-16.
18. Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, Kawakami T, et al. Wnt antagonist family genes as biomarkers for diagnosis, staging and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006; 12:6989-97.
19. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007; 13:4740-9.
20. Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 2007; 13:6122-9.
21. Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays na important role in bladder cancer through aberrant canonical Wnt/β-catenin signaling pathway. Clin Cancer Res 2006; 12:383-91.
22. Neuhausen A, Florl AR, Grimm M-O, Schulz WA. DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther 2006; 5:993-1001.
23. Sarrió D, Moreno-Bueno G, Hardisson D, Sánchez-Estévez C, Guo M, Herman JG, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expresion and microsatellite instability. Int J Cancer 2003; 106:208-15.
24. Rubin JS, Barshishat-Kupper M, Feroze-Merzoug F, Xi ZF. Secreted WNT antagonists as tumor suppressors: pro and con. Front Biosci 2006; 11:2093-105.
25. Florl AR, Steinhoff C, Muller M, Seifert H-H, Hader C, Engers R, et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-I hypomethylation. Br J Cancer 2004; 91:985-94.
26. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005; 65:4218-27.
27. Joesting MS, Cheever TR, Volzing KG, Yamaguchi TP, Wolf V, Naf D. Secreted frizzled related protein 1 is a paracrine modulator of epithelial branching morphogenesis, proliferation, and secretory gene expression in the prostate. Dev Biol 2008; 317:161-73.
28. Lu W, Tinsley HN, Keeton A, Qu Z, Piazza GA, Li Y. Suppression of Wnt/β-catenin signaling inhibits prostate cancer cell proliferation. European J Pharmacology 2009; 602:8-14.
29. Calviello G, Resci F, Serini S, Piccioni E, Toesca A, Boninsegna A, et al. Docosahexaenoic acid induces proteasome-dependent degradation of β-catenin, downregulation of survivin, and apoptosis in human colorectal cancer cells not expressing COX-2. Carcinogenesis 2007; 28:1202-9.
30. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Part 1: Tumors of the kidney. In World health organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Lyon (France): IARC Press 2004; 9-43.
31. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111:58-64.
32. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655-63.
33. th ed. Geneva: UICC 2002.
34. Pearson H, Stirling D. DNA extraction from tissue. Methods Mol Biol 2003; 226:33-4.
35. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994; 22:2990-7.
36. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28:32.
37. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001; 61:3410-8.
38. Henrique R, Jerónimo C, Teixeira MR, Hoque MO, Carvalho AL, Pais I, et al. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 2006; 4:1-8.
39. Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, et al. Hypermethylation of cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med 2006; 84:911-8.
40. Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, Lobo F, et al. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 2007; 7:133.